DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a price-to-earnings (PE) ratio of 27.7 in the Healthcare sector.

What is the market capitalisation of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a market capitalisation of approximately ₹22 crore.

Ishita Drugs & Industries Ltd

524400·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹22 Cr

P/E27.70

Vol—

Day—

52W66–91

Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

O—H—L—PC—VWAP—VOL—

52W₹66.00

₹90.85

Snapshot

Key stats

Mkt Cap

₹22 Cr

P/E

27.70Fair

P/B

1.86

ROE

6.98%Weak

ROCE

9.91%Weak

52W High / Low

₹91 / ₹66

Div Yield

0.00%

EPS

₹2.91

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

27.7Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

7.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

9.9%Weak

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹22 Cr

P/B

1.86

EPS

₹2.91

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.7%

+1.0%

10Y

+7.5%

Profit

+10.4%

-1.2%

10Y

+18.7%

EPS

+8.8%

-2.1%

10Y

+18.2%

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 1.00% over past five years.
Company has a low return on equity of 7.72% over last 3 years.
Earnings include an other income of Rs.0.47 Cr.
Working capital days have increased from 65.9 days to 146 days

More Healthcare stocks · Pharmaceuticals

Explore Ishita Drugs & Industries Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.